Gateway inspections are due to commence spring 2019 as the first stage of a new GDP inspection approach which will allow MHRA to increase its level of oversight whilst reducing the regulatory burden on those companies with a large number of sites which perform reduced or limited levels of GDP activity.
Cheryl Blake is Senior GDP Inspector, she joined the MHRA in 2005. Cheryl is a Chartered Chemist and spent many years working within industry as a research chemist during which time she filed a number of patents both European and Worldwide. She also has extensive experience working within Project and Programme Management roles with responsibility for a wide range of projects spanning various Scientific and Engineering disciplines.
Those of you who attended our symposiums in either Glasgow or London during December 2016 will have heard Jane Sewell – International Trade Development Liaison Officer from HMRC speak about the Unified Customs Code.
Related content and links
About the MHRA Inspectorate Blog
This blog shares the work of the Medicines and Healthcare products Regulatory Agency (MHRA) Inspectorate, by inspectors and those the Inspectorate works with.
MHRA Inspectorate & Process Licensing Organogram
Other MHRA Blogs
Comments and moderation
- Inspectors grounded - a year of innovation
- Pharmacovigilance inspection metrics April 2019 to March 2020
- Guidance on pharmacovigilance requirements for UK authorised products from 1 January 2021
- Reference Safety Information (RSI) for Clinical Trials- Part III
- Pharmacovigilance requirements for UK authorised products - 13 January 2021